Estimating disparities of prostate cancer burden and its attributable risk factors for males across the BRICS‐plus, 1990–2019: A comparable study of key nations with emerging economies
Fuente:
Wiley Open Access
Guardado en:
| Autores principales: | Li‐Sha Luo, Jiao Huang, Hang‐Hang Luan, Sumaira Mubarik, Quliang Zhong, Xian‐Tao Zeng |
|---|---|
| Formato: | Artículo Open Access |
| Publicado: |
Wiley
2024
|
| Materias: | |
| Acceso en línea: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
Assessing state‐of‐the‐art online large language models for patient education regarding prostatitis
por: Pengfei Zhang, et al.
Publicado: (2024)
por: Pengfei Zhang, et al.
Publicado: (2024)
Dose modification in enzalutamide and abiraterone plus prednisolone for castration‐resistant prostate cancer: A subanalysis from the ENABLE study for PCa
por: Nobumichi Tanaka, et al.
Publicado: (2024)
por: Nobumichi Tanaka, et al.
Publicado: (2024)
Consistent predictive ability of prostate‐specific antigen density prediction model for clinically significant prostate cancer across age strata
por: Kamil Malshy, et al.
Publicado: (2024)
por: Kamil Malshy, et al.
Publicado: (2024)
Bellmunt risk score as a survival predictor in patients with metastatic castration‐resistant prostate cancer
por: Thomas Büttner, et al.
Publicado: (2024)
por: Thomas Büttner, et al.
Publicado: (2024)
Differences in real‐world outcomes by risk classification for localized prostate cancer patients after radiation therapy
por: Lawrence Karsh, et al.
Publicado: (2024)
por: Lawrence Karsh, et al.
Publicado: (2024)
Incidence and risk factors of prostate cancer among the Northern and Eastern parts of the United Arab Emirates population
por: Jian Wang, et al.
Publicado: (2024)
por: Jian Wang, et al.
Publicado: (2024)
Modern predictors and management of incidental prostate cancer at holmium enucleation of prostate
por: Eric V. Li, et al.
Publicado: (2024)
por: Eric V. Li, et al.
Publicado: (2024)
Does larger prostate size provide protection for cancer specific outcomes in localized prostate cancer
por: Zain Abedali, et al.
Publicado: (2024)
por: Zain Abedali, et al.
Publicado: (2024)
Impact of definitive radiotherapy on metabolic response measured with 68Ga‐PSMA‐PET/CT in patients with intermediate‐risk prostate cancer
por: Cem Onal, et al.
Publicado: (2024)
por: Cem Onal, et al.
Publicado: (2024)
Cutibacterium acnes invades prostate epithelial cells to induce BRCAness as a possible pathogen of prostate cancer
por: Shingo Ashida, et al.
Publicado: (2024)
por: Shingo Ashida, et al.
Publicado: (2024)
Diagnosis and management of neuroendocrine prostate cancer
por: Ivan de Kouchkovsky, et al.
Publicado: (2024)
por: Ivan de Kouchkovsky, et al.
Publicado: (2024)
Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki67
por: Fengnian Zhao, et al.
Publicado: (2024)
por: Fengnian Zhao, et al.
Publicado: (2024)
The effect of dose‐escalation radiotherapy with simultaneous‐integrated‐boost on the use of short‐term androgen deprivation therapy in patients with intermediate risk prostate cancer
por: Cem Onal, et al.
Publicado: (2024)
por: Cem Onal, et al.
Publicado: (2024)
Other‐cause mortality in incidental prostate cancer
por: Francesco Di Bello, et al.
Publicado: (2024)
por: Francesco Di Bello, et al.
Publicado: (2024)
Influence of microbiome in intraprostatic inflammation and prostate cancer
por: Pranav Prakash, et al.
Publicado: (2024)
por: Pranav Prakash, et al.
Publicado: (2024)
Analysis of three primary prostatic sarcoma cases and literature review
por: Yirui Wei, et al.
Publicado: (2024)
por: Yirui Wei, et al.
Publicado: (2024)
FOXA1 regulates ribosomal RNA transcription in prostate cancer
por: Tianwei Jia, et al.
Publicado: (2024)
por: Tianwei Jia, et al.
Publicado: (2024)
Translation and validation of a lifestyle questionnaire related to prostate cancer
por: Reyhane Karegar‐Niavol, et al.
Publicado: (2024)
por: Reyhane Karegar‐Niavol, et al.
Publicado: (2024)
Prognostic model for second progression‐free survival and overall survival in patients with high‐risk metastatic hormone‐sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy
por: Shintaro Narita, et al.
Publicado: (2024)
por: Shintaro Narita, et al.
Publicado: (2024)
Key learnings from concordant systematic biopsies in prostate‐specific membrane antigen positron emission tomography/computed tomography‐guided prostate biopsies: Enhancing targeting accuracy
por: Thomas Büttner, et al.
Publicado: (2024)
por: Thomas Büttner, et al.
Publicado: (2024)
The role of gut microbiota involved in prostate microenvironment and symptoms improvement in chronic prostatitis/chronic pelvic pain syndrome patients treated with low‐intensity extracorporeal shock wave
por: Xiangbin Kong, et al.
Publicado: (2024)
por: Xiangbin Kong, et al.
Publicado: (2024)
Investigation of pelvic floor influence on prostate displacement in image‐guided radiotherapy
por: Hongbo Chai, et al.
Publicado: (2024)
por: Hongbo Chai, et al.
Publicado: (2024)
Three‐dimensional ultrastructural and anatomical analysis of prostatic neuroendocrine cells in mice
por: Kei‐Ichiro Uemura, et al.
Publicado: (2024)
por: Kei‐Ichiro Uemura, et al.
Publicado: (2024)
Ejaculatory and erectile function outcomes following holmium laser enucleation of the prostate
por: Chinade Roper, et al.
Publicado: (2024)
por: Chinade Roper, et al.
Publicado: (2024)
Retrospective analysis of the learning curve in perineal robot‐assisted prostate biopsy
por: Ruth Himmelsbach, et al.
Publicado: (2024)
por: Ruth Himmelsbach, et al.
Publicado: (2024)
The detection rate for prostate cancer in systematic and targeted prostate biopsy in biopsy‐naive patients, according to the localization of the lesion at the mpMRI: A single‐center retrospective observational study
por: Matteo Massanova, et al.
Publicado: (2024)
por: Matteo Massanova, et al.
Publicado: (2024)
Size and SUVmax define the contribution of nodal metastases to PSA in oligorecurrent prostate cancer
por: Fabian Falkenbach, et al.
Publicado: (2024)
por: Fabian Falkenbach, et al.
Publicado: (2024)
Cumulative cancer locations on prostate biopsy and active surveillance outcomes in the MRI era
por: Sean A. Fletcher, et al.
Publicado: (2024)
por: Sean A. Fletcher, et al.
Publicado: (2024)
Lower urinary tract symptoms in elderly men: Considerations for prostate cancer testing
por: Stephen Schmit, et al.
Publicado: (2024)
por: Stephen Schmit, et al.
Publicado: (2024)
Performance of large language models on benign prostatic hyperplasia frequently asked questions
por: YuNing Zhang, et al.
Publicado: (2024)
por: YuNing Zhang, et al.
Publicado: (2024)
L1CAM mediates neuroendocrine phenotype acquisition in prostate cancer cells
por: Chia‐Ling Hsieh, et al.
Publicado: (2024)
por: Chia‐Ling Hsieh, et al.
Publicado: (2024)
Testosterone bounce predicts favorable prognoses for prostate cancer patients treated with degarelix
por: Shuhei Kamada, et al.
Publicado: (2024)
por: Shuhei Kamada, et al.
Publicado: (2024)
Development and validation of an imageless machine‐learning algorithm for the initial screening of prostate cancer
por: Nicolas Martelin, et al.
Publicado: (2024)
por: Nicolas Martelin, et al.
Publicado: (2024)
Clinical and histopathological parameters in transrectal ultrasound‐guided biopsies associated with tumor upgrading after radical prostatectomy: A comparative analysis of risk groups
por: Mustafa Ozkaya, et al.
Publicado: (2024)
por: Mustafa Ozkaya, et al.
Publicado: (2024)
Distribution of neurovascular structures within the prostate gland and their relationship to complications after radical prostatectomy
por: Ghazi Alanazi, et al.
Publicado: (2024)
por: Ghazi Alanazi, et al.
Publicado: (2024)
Outcomes of 10 years of PSA screening for prostate cancer in Norwegian men with Lynch syndrome
por: Eli Marie Grindedal, et al.
Publicado: (2024)
por: Eli Marie Grindedal, et al.
Publicado: (2024)
Serum levels of prostate specific antigen, free PSA, [−2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacotherapy
por: Michal Jirásko, et al.
Publicado: (2024)
por: Michal Jirásko, et al.
Publicado: (2024)
Real‐world study: Impact of multidisciplinary management of apalutamide‐associated adverse events in prostate cancer
por: Julián Córdoba Sánchez, et al.
Publicado: (2024)
por: Julián Córdoba Sánchez, et al.
Publicado: (2024)
Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone‐sensitive prostate cancer: A multicenter study
por: Takafumi Yanagisawa, et al.
Publicado: (2024)
por: Takafumi Yanagisawa, et al.
Publicado: (2024)
PIK3/Akt/mTOR pathway alterations in metastatic castration‐sensitive prostate cancer
por: Philip Sutera, et al.
Publicado: (2024)
por: Philip Sutera, et al.
Publicado: (2024)
Ejemplares similares
-
Assessing state‐of‐the‐art online large language models for patient education regarding prostatitis
por: Pengfei Zhang, et al.
Publicado: (2024) -
Dose modification in enzalutamide and abiraterone plus prednisolone for castration‐resistant prostate cancer: A subanalysis from the ENABLE study for PCa
por: Nobumichi Tanaka, et al.
Publicado: (2024) -
Consistent predictive ability of prostate‐specific antigen density prediction model for clinically significant prostate cancer across age strata
por: Kamil Malshy, et al.
Publicado: (2024) -
Bellmunt risk score as a survival predictor in patients with metastatic castration‐resistant prostate cancer
por: Thomas Büttner, et al.
Publicado: (2024) -
Differences in real‐world outcomes by risk classification for localized prostate cancer patients after radiation therapy
por: Lawrence Karsh, et al.
Publicado: (2024)